Alpha 2.0
Login Register
» Articles » PMID: 33657247

Dupilumab and Conjunctivitis: a Case Series of Twenty Patients

Overview
Journal J Eur Acad Dermatol Venereol
Specialty Infectious Diseases
Date 2021 Mar 3
PMID 33657247
Citations 7
Authors
G Calabrese
A Gambardella
G Licata
E V Di Brizzi
R Alfano
G Argenziano
Affiliations
Soon will be listed here.
Citing Articles

Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice.

Paganini C, Spelta S, Tofani L, Talamonti M, Bianchi L, Coassin M J Clin Med. 2024; 13(13).

PMID: 38999383 PMC: 11242834. DOI: 10.3390/jcm13133818.

Dupilumab-associated ocular surface disease or atopic keratoconjunctivitis not improved by dupilumab? Upadacitinib may clarify the dilemma: A case report.

Galluzzo M, Tofani L, Spelta S, Talamonti M, Micera A, Bianchi L Skin Health Dis. 2024; 4(3):e354.

PMID: 38846697 PMC: 11150752. DOI: 10.1002/ski2.354.

Peripheral ulcerative keratitis associated with tralokinumab therapy: a case report and review of IL-13 inhibitor-associated ocular surface disease.

Maganti N, Whittier S, Warner E J Ophthalmic Inflamm Infect. 2024; 14(1):15.

PMID: 38625674 PMC: 11021381. DOI: 10.1186/s12348-024-00394-1.

Dupilumab-Induced, Tralokinumab-Induced, and Belantamab Mafodotin-Induced Adverse Ocular Events-Incidence, Etiology, and Management.

Mickevicius T, Pink A, Bhogal M, OBrart D, Robbie S Cornea. 2022; 42(4):507-519.

PMID: 36525340 PMC: 9973444. DOI: 10.1097/ICO.0000000000003162.

Therapeutic effect of chinese herbal medicine gu-ben-hua-shi (AESS) formula on atopic dermatitis through regulation of yes-associated protein.

Jia J, Feng L, Ye S, Ping R, Mo X, Zhang Y Front Pharmacol. 2022; 13:929580.

PMID: 36313294 PMC: 9597468. DOI: 10.3389/fphar.2022.929580.